{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T21:38:50Z","timestamp":1698183530564},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2002,11]]},"DOI":"10.1007\/s11894-002-0028-9","type":"journal-article","created":{"date-parts":[[2007,5,19]],"date-time":"2007-05-19T16:12:29Z","timestamp":1179591149000},"page":"513-516","source":"Crossref","is-referenced-by-count":12,"title":["Treatment of the extraintestinal manifestations of inflammatory bowel disease"],"prefix":"10.1007","volume":"4","author":[{"given":"Charles N.","family":"Bernstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"28_CR1","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1053\/gast.2001.29686","volume":"121","author":"P Koutkia","year":"2001","unstructured":"Koutkia P, Lu Z, Chen TC, Holick MF: Treatment of vitamin D deficiency due to Crohn\u2019s disease with tanning bed ultraviolet B radiation. Gastroenterology 2001, 121:1485\u20131488.","journal-title":"Gastroenterology"},{"key":"28_CR2","first-page":"147","volume-title":"Trends in Inflammatory Bowel Disease Therapy.","author":"CN Bernstein","year":"1999","unstructured":"Bernstein CN: Risk factors and prevalence of bone disease in inflammatory bowel disease. In Trends in Inflammatory Bowel Disease Therapy. Edited by Williams CN, Bursey RF, Gall DG, et al. Dordrecht: Kluwer Academic Publishers; 1999:147\u2013162."},{"key":"28_CR3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0140-6736(00)03560-1","volume":"357","author":"MF Holick","year":"2001","unstructured":"Holick MF: Sunlight \"D\"ilemma: risk of skin cancer or bone disease and muscle weakness. Lancet 2001, 357:401\u2013506.","journal-title":"Lancet"},{"key":"28_CR4","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","volume":"96","author":"CN Bernstein","year":"2001","unstructured":"Bernstein CN, Blanchard JF, Rawsthorne P, Yu N: The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 2001, 96:1116\u20131122. This is the first North American population-based study of extraintestinal manifestations in IBD.","journal-title":"Am J Gastroenterol"},{"key":"28_CR5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/art.1780391013","volume":"39","author":"AA Grom","year":"1996","unstructured":"Grom AA, Murray KJ, Luyrink L, et al.: Patterns of expression of tumor necrosis factor alpha, bdtumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondyloarthropathy. Arthritis Rheum 1996, 39:1703\u20131710.","journal-title":"Arthritis Rheum"},{"key":"28_CR6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","volume":"38","author":"J Braun","year":"1995","unstructured":"Braun J, Bellow M, Neure L, et al.: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995, 38:499\u2013505.","journal-title":"Arthritis Rheum"},{"key":"28_CR7","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","volume":"346","author":"JD Gorman","year":"2002","unstructured":"Gorman JD, Sack KE, Davis JC Jr: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor. N Engl J Med 2002, 346:1349\u20131356. This important randomized, controlled study proves the value of modulating TNF-\u2019a in ankylosing spondylitis.","journal-title":"N Engl J Med"},{"key":"28_CR8","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","volume":"122","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ, Hanauer SB, Katz S, et al.: Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebocontrolled trial. Gastroenterology 2001, 122:1088\u20131094.","journal-title":"Gastroenterology"},{"key":"28_CR9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group. N Engl J Med 1997, 337:1029\u20131035.","journal-title":"N Engl J Med"},{"key":"28_CR10","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","volume":"43","author":"J Brandt","year":"2000","unstructured":"Brandt J, Haibel H, Cornely D, et al.: Successful treatment of active ankylosing spondylitis with anti-tumor necrosis factor-alpha monoclonal antibody infliximab. Arthritis Rheum 2000, 43:1346\u20131352.","journal-title":"Arthritis Rheum"},{"key":"28_CR11","first-page":"1605","volume":"28","author":"M Stone","year":"2001","unstructured":"Stone M, Salonen D, Lax M, et al.: Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001, 28:1605\u20131614.","journal-title":"J Rheumatol"},{"key":"28_CR12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/0167-5699(96)80599-8","volume":"17","author":"G Michel","year":"1996","unstructured":"Michel G, Kemeny L, Homey B, Ruzicka T: FK506 in the treatment of inflammatory skin disease: promises and perspectives. Immunol Today 1996, 17:106\u2013108.","journal-title":"Immunol Today"},{"key":"28_CR13","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJM199709183371203","volume":"337","author":"T Ruzicka","year":"1997","unstructured":"Ruzicka T, Bieber T, Schopf E, et al.: A short term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997, 337:816\u2013821.","journal-title":"N Engl J Med"},{"key":"28_CR14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000211510","volume":"10","author":"AI Lauerma","year":"1997","unstructured":"Lauerma AI, Surber C, Maibach HI: Absorption of topical tacrolimus (FK506) in vitro through human skin: comparison with cyclosporin A. Skin Pharmacol 1997, 10:230\u2013234.","journal-title":"Skin Pharmacol"},{"key":"28_CR15","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(05)78962-5","volume":"351","author":"H-C Schuppe","year":"1998","unstructured":"Schuppe H-C, Homey B, Assman T, et al.: Topical tacrolimus for pyoderma gangrenosum. Lancet 1998, 351:832.","journal-title":"Lancet"},{"key":"28_CR16","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/gut.47.3.436","volume":"47","author":"DH Casson","year":"2000","unstructured":"Casson DH, Eltumi M, Tomlin S, et al.: Topical tacrolimus may be effective in the treatment of oral and perineal Crohn\u2019s disease. Gut 2000, 47:436\u2013440. This study offers an important reminder to gastroenterologists about the use of topical tacrolimus for dermatologic manifestations of IBD.","journal-title":"Gut"},{"key":"28_CR17","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1053\/jhsu.2001.24962","volume":"26A","author":"SB Huish","year":"2001","unstructured":"Huish SB, de la Paz EM, Ellis PR III, Stern PJ: Pyoderma gangrenosum of the hand: a case series and review of the literature. J Hand Surg 2001, 26A:679\u2013685.","journal-title":"J Hand Surg"},{"key":"28_CR18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0266-7681(93)90209-X","volume":"18B","author":"RE Brown","year":"1993","unstructured":"Brown RE, Lay L, Graham D: Bilateral pyoderma gangrenosum of the hand: treatment with dapsone. J Hand Surg 1993, 18B:119\u2013121.","journal-title":"J Hand Surg"},{"key":"28_CR19","first-page":"930","volume":"137","author":"M-H Tan","year":"2001","unstructured":"Tan M-H, Gordon M, Lebwohl O, et al.: Improvement in pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor a monoclonal antibody. Arch Dermatol 2001, 137:930\u201333.","journal-title":"Arch Dermatol"},{"key":"28_CR20","first-page":"A616","volume":"122","author":"M Reguerio","year":"2002","unstructured":"Reguerio M, Plevy S, Valentine J, et al.: Successful treatment of IBD-associated pyoderma gangrenosum with infliximab [abstract]. Gastroenterology 2002, 122:A616.","journal-title":"Gastroenterology"},{"key":"28_CR21","first-page":"A618","volume":"122","author":"E Foster","year":"2002","unstructured":"Foster E, Nguyen KK, Bolce R, Prindiville TP: Cutaneous manifestations of inflammatory bowel disease improve with infliximab therapy [abstract]. Gastroenterology 2002, 122:A618.","journal-title":"Gastroenterology"},{"key":"28_CR22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.7326\/0003-4819-134-2-200101160-00008","volume":"134","author":"BY Tung","year":"2001","unstructured":"Tung BY, Emond MJ, Haggitt RC, et al.: Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001, 134:89\u201395.","journal-title":"Ann Intern Med"},{"key":"28_CR23","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/jhep.2002.30695","volume":"35","author":"I Dvorchik","year":"2002","unstructured":"Dvorchik I, Subotin M, Demetris AJ, et al.: Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology 2002, 35:380\u2013384.","journal-title":"Hepatology"},{"key":"28_CR24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1155\/2002\/204614","volume":"16","author":"H Ben-Ami","year":"2002","unstructured":"Ben-Ami H, Ginesin Y, Behar DM, et al.: Diagnosis and treatment of urinary tract complications in Crohn\u2019s disease: an experience over 15 years. Can J Gastroenterol 2002, 16:225\u2013229.","journal-title":"Can J Gastroenterol"},{"key":"28_CR25","first-page":"505","volume":"93","author":"DS Pardi","year":"1998","unstructured":"Pardi DS, Tremaine WJ, Sandborn WJ, et al.: Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol 1998, 93:505\u2013514.","journal-title":"Am J Gastroenterol"},{"key":"28_CR26","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00054725-200111000-00003","volume":"7","author":"AL Wester","year":"2001","unstructured":"Wester AL, Vatn MH, Fausa O: Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis 2001, 7:295\u2013300.","journal-title":"Inflamm Bowel Dis"},{"key":"28_CR27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1155\/2001\/954340","volume":"15","author":"CL Nash","year":"2001","unstructured":"Nash CL, Pannacione R, Sutherland LR, Meddings JB: Giant cell myocarditis in a patient with Crohn\u2019s disease, treated with etanercept\u2014a tumor necrosis factor-alpha antagonist. Can J Gastroenterol 2001, 15:607\u2013611.","journal-title":"Can J Gastroenterol"},{"key":"28_CR28","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1161\/01.CIR.99.25.3224","volume":"99","author":"A Deswal","year":"1999","unstructured":"Deswal A, Bozkurr B, Seta Y, et al.: Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999, 99:3224\u20133226.","journal-title":"Circulation"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-002-0028-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-002-0028-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-002-0028-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:03:42Z","timestamp":1559419422000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-002-0028-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,11]]}},"alternative-id":["28"],"URL":"https:\/\/doi.org\/10.1007\/s11894-002-0028-9","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,11]]}}}